Form 4: Twist Bioscience Officer Sells Shares for Tax Obligations

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reported sales of common stock.
• The transactions occurred on November 21, 2025, and November 24, 2025.
• A total of 229 shares were sold at $26.5035 per share on November 21, 2025.
• An additional 822 shares were sold at $28.7095 per share on November 24, 2025.
• These sales were non-discretionary "sell to cover" transactions, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon RSU vesting.
• Following these transactions, Robert F. Werner beneficially owns 66,143 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports routine, non-discretionary "sell to cover" transactions by an officer to satisfy tax obligations related to RSU vesting. These are standard events and do not reflect a change in management's confidence or the company's operational performance, thus having a neutral impact on sentiment.

Positives

• The sales were non-discretionary, indicating they were not driven by a lack of confidence in the company's future performance.
• The transactions are part of a routine process for equity compensation, demonstrating standard corporate governance practices for executive compensation.

Negatives

• No discretionary sales by the reporting person were made, so no negative signal regarding management's outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

Sell to cover transactions are a common and routine practice across industries for executives and employees receiving equity compensation, particularly Restricted Stock Units (RSUs), to satisfy tax liabilities upon vesting. This filing reflects a standard operational aspect of executive compensation at Twist Bioscience Corp, aligning with typical practices in the biotechnology and life sciences sectors where equity-based incentives are prevalent.

Comparison to Industry Standards

• "Sell to cover" transactions are a standard mechanism for satisfying tax obligations arising from equity compensation across all industries. For example, executives at tech giants like Apple (AAPL) or pharmaceutical companies like Pfizer (PFE) frequently engage in similar non-discretionary sales when their RSUs vest.
• This practice is widely accepted and does not typically signal a change in management's confidence, unlike discretionary open-market sales.
• The reported transactions are consistent with common corporate governance and compensation practices observed in publicly traded companies.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in management's outlook. The total number of shares sold is relatively small compared to the company's overall outstanding shares.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider transaction, Stock sale, Restricted Stock Units, RSU vesting, Tax withholding, Chief Accounting Officer, Robert F. Werner